Compare Quest Diagnostics Inc (DGX) vs Logitech International SA (LOGI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Logitech International SA — how do they compare? Quest Diagnostics Inc trades at $235.39 (market cap $26.21B), while Logitech International SA trades at $104.02 (market cap $14.96B). The key difference: Quest Diagnostics Inc is the larger of the two by market cap, and Logitech International SA pays the higher dividend (1.64%). Which is the better fit depends on your goals.
| DGX | LOGI | |
|---|---|---|
Market Cap | $26.21B | $14.96B |
Sector | Health | Technology |
52-Week High | $238.50 | $126.69 |
52-Week Low | $173.49 | $85.84 |
Enterprise Value | $31.97B | $13.30B |
Dividend Yield | 1.45% | 1.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.63, down slightly by 0.3% today, but maintains strong momentum with three consecutive quarterly earnings beats and a raised 2026 outlook. The stock shows bullish technical signals with moving averages supporting upward trends, while fundamentals reveal solid revenue growth to $11.04 billion in 2025 and improving profit margins. Recent news highlights surging testing demand and AI implementation driving operational efficiency.
DGX presents a favorable investment case with analyst consensus price target of $249.50 offering 5% upside potential. Strong testing demand, strategic partnerships, and earnings momentum support growth, though elevated debt levels and margin pressures from lower-margin deals pose moderate risks. The stock's current valuation at 25.21 P/E appears reasonable given growth prospects.
Logitech (LOGI) trades at $104.87, down 1.37% on the day, with a neutral technical signal and mixed analyst sentiment. Recent Q1 2027 earnings beat estimates with EPS of $1.85 versus $1.26 expected, driven by tariff refunds and premium demand, though a key supplier shutdown clouds near-term outlook. Fundamentals show strong profitability with a 16.28% net margin and 35.29% ROE, while valuation metrics like a P/E of 19.03 appear reasonable. The stock faces resistance near $109, with support at $104.
The outlook is cautiously optimistic given solid earnings momentum and margin expansion, but supply chain disruptions pose a near-term risk. Upside to the $109.75 consensus price target offers potential, though investor sentiment is divided amid operational uncertainties. Key risks include supplier dependency and competitive pressures in the tech peripherals market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Logitech International SA
Logitech International SA is a Switzerland-based provider of personal computer and mobile accessories for navigation, video communication, and collaboration, smart home, and other applications. Its product portfolio includes mice, keyboards, charging stands, tablet cases, car mounts for mobile devices, remotes, home cameras, home switches, controllers, bluetooth speakers, surround sound, webcams, and conference cameras. It operates in a single segment namely, Peripherals. The firm generates revenue from the Americas, EMEA (Europe, Middle East, Africa), and the Asia Pacific region.
Read more on LOGI →
